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Abstract
Background: Most infarctions occur in the left anterior descending coronary artery and cause myocardium damage
of the left ventricle. Although current pluripotent stem cells (PSCs) and directed cardiac differentiation techniques
are able to generate fetal-like human cardiomyocytes, isolation of pure ventricular cardiomyocytes has been
challenging. For repairing ventricular damage, we aimed to establish a highly efficient purification system to obtain
homogeneous ventricular cardiomyocytes and prepare engineered human ventricular heart muscles in a dish.
Methods: The purification system used TALEN-mediated genomic editing techniques to insert the neomycin or
EGFP selection marker directly after the myosin light chain 2 (MYL2) locus in human pluripotent stem cells. Purified
early ventricular cardiomyocytes were estimated by immunofluorescence, fluorescence-activated cell sorting,
quantitative PCR, microelectrode array, and patch clamp. In subsequent experiments, the mixture of mature
MYL2-positive ventricular cardiomyocytes and mesenchymal cells were cocultured with decellularized natural
heart matrix. Histological and electrophysiology analyses of the formed tissues were performed 2 weeks later.
Results: Human ventricular cardiomyocytes were efficiently isolated based on the purification system using G418
or flow cytometry selection. When combined with the decellularized natural heart matrix as the scaffold, functional
human ventricular heart muscles were prepared in a dish.
Conclusions: These engineered human ventricular muscles can be great tools for regenerative therapy of human
ventricular damage as well as drug screening and ventricular-specific disease modeling in the future.
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Background
Myocardial infarction (MI) and subsequent cardiac damage
and remodeling remains the leading cause of morbidity
and mortality in the world. Owing to the anatomic size of
human ventricular heart chambers and the hemodynamic
features of the coronary arteries after sclerosis, most MI
patients present in the clinics exhibit ventricular myocar-
dium ischemia and dysfunction [1]. Therefore, repairing
the damaged ventricular cardiac muscles is the central
quest for current cardiac regenerative therapies.
Human pluripotent stem cells (hPSCs), including hu-
man embryonic stem cells (hESCs) and human induced
pluripotent stem cells (hiPSCs), offered new opportun-
ities for regenerative therapy of human MI [2, 3]. Large-
scale production of human cardiomyocytes is now
achievable through directed differentiation of hPSCs to
the cardiac lineage [4–7], which is able to provide
abundant human cardiomyocytes for bioengineering
human heart tissues and for cell therapy of myocardial
damage. However, cardiac differentiation of hPSCs results
in multiple subtypes of cells, including ventricular-like,
atrial-like, and sinus nodal-like cardiomyocytes as well as
cells of other lineages. Ventricular, atrial, and sinus nodal
cardiomyocytes exhibited different physical and electro-
physiological properties [8–10]. A mixture of different
subtypes of cardiomyocytes may cause multiple sites of
ectopic electroactivities and arrhythmia after transplant-
ation into injured myocardium. Indeed, recent studies on
transplantation of suspended hESC-derived or hiPSC-
derived cardiomyocytes into the ventricles of nonhuman
primates eventually led to a different extent of ventricular
arrhythmia [11, 12]. Previous studies have made efforts to
isolate working-type cardiomyocytes. One study used a
molecular beacon targeting working-type CM-associated
markers [13]; Karakikes et al. attempted to develop a di-
rected ventricular-like cardiomyocyte differentiation sys-
tem using small molecules and growth factors [14]. For
the purpose of human heart tissue engineering or repair-
ing ventricular muscle damage, using a homogeneous
population of ventricular-specific myocytes would be
more attractive.
Since currently there are no specific surface markers
for ventricular cardiomyocytes, selection of ventricular
myocytes usually relies on endogenous genes expressed
specifically in ventricular heart muscles or cardiomyo-
cytes. Myosin light chain-2, the regulatory light chain
of myosin, is a critical component of the sarcomere of
striated muscles. The cardiac ventricular isoform of
myosin light chain-2 (MLC-2v, gene name MYL2) is re-
strictively expressed in the ventricular segment of the
heart tube at E8.0 in mice and remains exclusively
expressed in ventricles until adulthood [15, 16]. MYL2 is
therefore a good genetic locus for driving ventricular-
specific gene expression and a specific marker for selection
of ventricular cardiomyocytes. Previous studies used
either lentivirus-based or adenovirus-based human
MYL2 promoter-driving fluorescent protein as a reporter
to select hPSC-derived early ventricular cardiomyocytes
[9, 17, 18]. They demonstrated that MLC-2v is a robust
marker for enriching early ventricular cardiomyocytes
after cardiac differentiation of hiPSCs. However, the limi-
tations of a virus-based technique are obvious, which raise
safety issues and may not be applicable in future clinical
treatment.
In this study, we inserted the neomycin or EGFP
selection cassette directly after the MYL2 gene locus in
hPSCs by TALEN-mediated genomic engineering.
Using the internal ribosome entry site (IRES) sequence
or P2A peptidase signal in between, both markers were
coexpressed with the ventricular-specific MLC-2v when
cardiomyocytes were differentiated from hPSCs. Highly
pure human early ventricular cardiomyocytes can then
be enriched by G418 selection or flow cytometry based
on the EGFP reporter, which provides a highly efficient
system for the purification of hPSC-derived ventricular
cardiomyocytes.
Engineered heart tissues (EHTs) represent a promising
therapy for myocardium damage in the future. Human
ventricular cardiac patches may be more valuable for the
treatment of MI since most infractions cause damage in
the ventricles. To our knowledge, preparation of human
ventricular heart muscles has not been reported to date.
With our selected MLC-2v-positive human early ven-
tricular cells, we now are able to generate engineered
human ventricular heart muscles in the current study.
By combining a fixed ratio of selected hPSC-derived hu-
man ventricular cardiomyocytes and mesenchymal cells
with pieces of decellularized natural rat heart extracellu-
lar matrix (ECM), engineered human ventricular heart
muscles of desired shape and size were constructed in a
dish. These engineered human ventricular heart muscles
have great potential in modeling ventricular heart diseases,
in drug screening, as well as for repairing individual-
specific ventricular damages in the future.
Methods
Construction of TALENs and donor vectors
We designed two targeting donor vectors, tagged by the
neomycin resistance cassette (donor 1) or EGFP (donor
2), which are connected by IRES and P2A respectively
and therefore driven by the endogenous MYL2 pro-
moter. To prevent disruption of target gene expression,
the tag was inserted in the adjacent intron downstream
of the last exon in the MYL2 gene. We used the internal
ribosome entry site (IRES) sequence in between the neo-
mycin coding sequences and the 5' MYL2 homologous
arm in the donor construct. We later found that, for the
EGFP donor construct with IRES in between the 5'
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MYL2 homologous arm and the EGFP coding sequences,
the expression of EGFP was hard to detect after cardiac
differentiation of the engineered hESC lines. We there-
fore used the P2A peptidase signal in between the MYL2
and EGFP coding sequences. The TAG stop codon of
the MYL2 gene was thus removed in the EGFP donor
construct. The 5′-homology arm and the 3′-homology
arm of the MYL2 targeting donor vector were amplified
by PCR, introducing overlapping oligonucleotides to fa-
cilitate subcloning into the vector.
Evaluation of the cutting efficiency for TALENs
The 293FT cells were obtained from Shanghai SiDanSai
Biotechnology Co. Ltd. Cultured cells were transfected
with TALEN plasmids. Genomic DNA was then ex-
tracted after 5 days of puromycin selection. The tar-
geted region was amplified for sequencing and T7
Endonuclease I-based Mutation Detection (New Eng-
land Biolab). Briefly, PCR products were denatured and
annealed before T7 Endonuclease I digestion, and fi-
nally analyzed by electrophoresis.
MYL2 targeting in hPSCs using TALEN-based homologous
recombination
The human ESC line H7 used in this study was obtained
from WiCell Research Institute under a specific Material
Transfer Agreement. The human iPSC line was derived
previously from human skin fibroblasts in our laboratory
[19] with informed consent approved by the Bioethics
Committee of Zhongshan Hospital affiliated to Fudan
University. hPSCs cultured on Matrigel (growth factor
reduced; BD Biosciences) were disassociated into single
cells with Accutase (Invitrogen). Three million cells were
electroporated with the TALEN pairs and targeting
donor vectors using the Neon Transfection System (Life
Technology). Cells were seeded into a Matrigel-coated
10-cm dish containing 8 ml mTeSR1 hPSC Medium
(Stem Cell Technology) for recovery at 37 °C with 5%
CO2. For the selection of transfected cells, 0.25 μg/ml
puromycin was used. Single clones were then picked ∼
2 weeks later to analyze whether the neomycin resistance
(donor 1) or EGFP (donor 2) cassette was successfully
inserted via homologous recombination using nested PCR
followed by gel electrophoresis and confirmed by DNA
sequencing. Correctly targeted clones were picked into
six-well plates, expanded, and transfected with plasmids
expressing Cre-recombinase to excise the loxP-flanked
puromycin resistance cassette.
Teratoma formation
SCID/NOD mice were purchased from Shanghai SLAC
Laboratory Animal Co. Ltd. One million undifferentiated
hPSCs were suspended in 20 μl Matrigel and injected
into the armpit of 8-week-old SCID/NOD mice. All rats
were maintained at 24 °C, with free access to food and
water. Six weeks after cell delivery, tumors were dis-
sected and fixed with 4% paraformaldehyde in PBS for
hematoxylin and eosin (H&E) staining.
Histology and immunofluorescence staining
Cells were fixed in 4% paraformaldehyde and perme-
abilized with 0.05% Triton-X100 followed by goat
serum blocking. H7 and hiPSC colonies were stained
with pluripotency marker antibodies OCT3/4 (Santa
Cruz), SOX2 (Abcam), Nanog (Santa Cruz), and
SSEA-4 (Abcam), whereas hPSC-derived cardiomyo-
cytes were stained with antibodies for cTNT (Abcam),
Sarcomeric α-actinin (Abcam), MYL2 (Proteintech),
MYL7 (Synaptic system), or EGFP (Proteintech) for 24 h
at 4 °C respectively. Cells were then incubated with Alexa
Fluor 594 or 488 at 37 °C for 1 h and subsequently coun-
terstained with DAPI. For rat hearts, heart tissues were
paraffin-embedded and sectioned, followed by H&E stain-
ing. The remaining tissues were embedded with optimal
cutting temperature compound (OCT; Sakura Finetek,
Japan) and sectioned into sections 8 mm thick. The slides
were then labeled with antibodies for Laminin (Thermo
Fisher Scientific), fibronectin (Abcam), and collagen III
(Abcam). Images were captured with a fluorescence
microscope Leica DMi8 (Leica).
Cardiac differentiation and culture
Both H7 and hiPSCs were differentiated into the cardio-
myocyte lineage following modified protocols described
by Lian et al. [6]. Seven to 9 days post differentiation, a
beating cluster of cells can be observed, while robust
spontaneous contraction occurs by day 10. Cultures
were maintained in DMEM with 10% FBS under a 37 °C
and 5% CO2 air environment.
G418 selection of MYL2-positive cardiomyocytes
At 22 days post cardiac differentiation, beating cells
were digested and seeded into 12-well plates. Then
100 μg/ml G418 (InvivoGen) was used for 7–8 days
for the selection of drug-resistant hPSC cardiomyo-
cytes, with medium change every 1–2 days.
Quantitative PCR analysis
Total RNA was isolated using the Trizol reagent (Life
Technologies) and 3 μg total RNA was used to synthesize
cDNA using the ReverTra Ace qPCR RT Kit (FSQ-101;
TOYOBO) according to the manufacturer's instructions.
Quantitative RT-RCR was performed using the SYBR®
Green Realtime PCR master mix (TOYOBO) on a CFX96™
Real-Time System instrument (BIO-RAD). Each reaction
was run in triplicate to minimize the variation. Gene ex-
pression values were normalized to the mean expression of
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the housekeeping gene GAPDH. Primer sequences are
listed in Additional file 1: Table S1.
Fluorescence-activated cell sorting analysis of hPSC-
derived cardiomyocytes
Dissociated cell suspension was filtered with a 40-μm
cell strainer (BD Falcon) to remove cell clumps, and
the cells were then fixed and permeabilized using BD
Cytofix/Cytoperm™ (BD Biosciences) for 30 min at
4 °C. Next, cells were incubated with the primary anti-
body, including the mouse anti-human TNNT2 anti-
body (Thermo Scientific) or the rabbit anti-human
MYL2 antibody (Proteintech), followed by appropriate
FITC or PE-conjugated secondary antibody. Cells were
washed twice in BD perm/wash buffer, centrifuged,
and resuspended in 200 μl PBS. To define the thresh-
old for positive fluorescence, the isotype control sam-
ple was incubated with secondary antibody only. Data
were collected using FACSCalibur (BD Biosciences)
and analyzed using FlowJo. A total of 10,000 gated
events were counted for each marker in three inde-
pendent experiments.
EGFP+ cell analysis and sorting
For the analysis of EGFP+ cardiomyocytes, dissociated
and filtered MYL2EGFP/w-hPSC-derived cardiomyocytes
were resuspended in PBS, and then acquired with the
FACSCalibur system (BD Biosciences). GFP-positive
cardiomyocytes were sorted using a BD FACSAria II
flow cytometer. After the cell sorting procedure, cells
were collected and plated as monolayers (~10,000 cells
per coverslip) on Matrigel-coated 12-well plates in
DMEM with 10% FBS. Medium was changed routinely
every 2 days.
Apoptosis assay
Living cells were washed with ice-cold PBS and labeled
with Alexa Fluor 647-conjugated Annexin V and PI, and
then incubated for 15 min in the dark as recommended.
Cells were detected in 1 h using the FACSCalibur system
(BD Biosciences).
Patch clamp
Cardiac action potentials were recorded in current-clamp
mode from single beating cardiomyocytes with the whole-
cell patch-clamp technique, using an EPC-10 amplifier
(HEKA, Lambrecht, Germany). Data were acquired using
PatchMaster software (HEKA) and digitized at 1 kHz.
Data analysis was performed using Igor Pro (Wavemetrics,
Portland, OR, USA) and Prism (Graphpad, La Jolla, CA,
USA). V-like, A-like, and N-like cardiomyocytes were
identified by action potential (AP) patterns recorded in
normal Tyrode’s solution containing 150 mM NaCl,
5.4 mM KCl, 1 mM MgCl2, 15 mM glucose, 1.8 mM
CaCl2, 1 mM Na-pyruvate, and 15 mM HEPES (pH 7.4
with NaOH). The pipette solution contained 150 mM
KCl, 5 mM NaCl, 2 mM CaCl2, 10 mM HEPES,
5 mM Mg-ATP, and 5 mM EGTA (pH 7.2 with KOH).
Neonatal rat ventricular cardiomyocyte isolation and
coculture
Neonatal rat ventricular cardiomyocyte (NRVM) cultures
were prepared from neonatal 1-day-old Sprague–Dawley
rats. The ventricles were finely minced and dissociated
with 0.075% collagenase I (Ameresco) and 0.8% Trypsin
(Thermo Fisher Scientific) four times, for 10 min each.
The resulting cell suspensions were passed through a cell
strainer (100-μm mesh pore size; BD Biosciences) to ob-
tain a single cell suspension, and were seeded in 12-well
cell culture plates (Corning Life Sciences). For establishing
cocultures, on the day of NRVM isolation the hPSC-CMs
were counted and mixed with the NRVMs in a ratio of 3:1
before plating. At day 1 of culture, cells were incubated
with Brdu (10 μg/ml; Sigma-Aldrich) to inhibit nonmyo-
cyte proliferation.
Cardiomyocyte maturation culture
Dissociated hPSC-derived cardiomyocytes at 20–21 days
post differentiation were plated onto Matrigel-coated six-
well plates in mature medium, which consists of RPMI
1640 without glucose (Gibco), 500 μg/ml bovine serum al-
bumin (Yeasen), 213 μg/ml L-ascorbic acid 2-phosphate
(Sigma-Aldrich) supplemented with 10 mM D-galactose
(Sigma-Aldrich), 4 mM L-lactic acid (Sigma-Aldrich),
1 mM sodium pyruvate (Sigma-Aldrich), 20 μg/ml insulin
(Sigma-Aldrich), 1× chemically defined lipid concentrate
(Sigma-Aldrich), and 200 ng/ml triiodo-L-thyronine
(Sigma-Aldrich). At day 2, the medium was supplemented
with 100 ng/ml G418 for another 7 days. From day 9, cells
were cultured in mature medium with a medium change
every other day.
Perfusion and decellularization of rat hearts
Hearts were obtained from 200–250 g adult rats and
cannulated into the ascending aorta with a blunt 20-
gauge needle to perform retrograde coronary perfusion.
First, sterile deionized water was perfused for 30 min at
2.0 ml/min, followed by perfusion with 1% sodium
dodecyl sulfate (SDS) for 3 h, and 1% triton X-100 with
0.5% EDTA (PH 8.0) for another 30 min. The hearts
were then washed with deionized water and phosphate
buffered saline (PBS) containing 100 U/ml penicillin
(Life Technologies, USA), 100 μg/ml streptomycin (Life
Technologies), and 1.25 μg/ml amphotericin B (Sigma-
Aldrich) for another 2 h.
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Generation of 3D ventricular heart muscles
The decellularized heart ECM was cut into pieces under
sterile conditions. The ECM pieces were then put in
wells of 48-well plates as a sheet. The mixture of ven-
tricular cardiomyocytes was then seeded onto the sheet
at 104 cells/mm2. The ventricular heart muscles were
cultured in the mature medium and changed every day.
Electrophysiological assessment of the ventricular heart
muscles
Beating ventricular heart muscles were plated on a 0.1%
gelatin-coated microelectrode array (MEA) probe for
2 days with mature medium and then examined by the
MEA data acquisition system MEA-2100 (Multi-channel
Systems). A 60-channel voltage amplifier system was used
for recording ventricular heart muscles. Data analysis was
performed with SPIKE2 software (CED.UK).
Statistical analysis
Data were presented as the SEM of three independent
experiments. Student’s t test was used to compare two
normally distributed data sets. To compare the statis-
tical differences of multiple groups, one-way analysis of
variance (ANOVA) was used. P < 0.05 was considered
statistically significant.
Results
Insertion of the neomycin or EGFP selection marker after
the MYL2 locus in hESCs by TALEN-mediated homologous
recombination
To insert the neomycin/EGFP selection marker under the
C-terminus of the MYL2 gene located on chromosome 12,
we used TALEN-mediated genomic editing techniques in
this study. The overall schema of the donor constructs
containing the neomycin or EGFP cassette, the specific
TALEN cutting sites on the adjacent intron downstream
of MYL2 exon 7, and the homologous recombination
events are illustrated in Fig. 1a. The design of the two
donor constructs was to allow the neomycin or EGFP to
be expressed along with, but separately from, MLC-2v
expression after insertion into the 3' terminal of the
MYL2 gene. The purpose of this design was to avoid
formation of fusion proteins which may severely affect
the normal function of MLC-2v, the myofilaments, and
the cardiomyocytes.
We designed and engineered six TALEN pairs (three left
(L) TALENs × two right (R) TALENs) targeting down-
stream of the TAG stop codon on exon 7 of the MYL2
gene. The L2 + R2 TALEN pair showed a ~20% cutting
efficiency by T7EI assays and was confirmed by DNA se-
quencing (Additional file 2: Figure S1), and thus was used
in the subsequent experiments. We next transfected H7
hESCs with the TALEN pair (L2 + R2) and the respective
donor construct by electroporation. Positive single clones
with successful homologous recombination were then
selected with puromycin. Nested PCR using primers flank-
ing the genomic sequence (5' primer) and the donor se-
quence (3' primer) showed that, in both the neomycin and
EGFP groups, 10 out of 14 picked single clones exhibited
successful homologous recombination (Fig. 1b). We next
transfected these positive clones with Cre recombinase
and removed the PGK-puromycin selection cassette. Final
DNA sequencing of the genomic sequence of the MYL2
allele confirmed the correct insertion of the neomycin or
EGFP cassette (Additional file 3: Figure S2). To see
whether our L2 + R2 TALEN pair caused off-target editing
that may cause unwanted mutations at another locus in
the genome of these positive clones, we amplified the top
10 potential off-target sites (obtained by TALENoffer soft-
ware [20]) by genomic PCR and performed DNA sequen-
cing. No off-target editing events were found (Additional
file 4: Table S2). We termed these heterozygous hESCs with
correct neomycin or EGFP insertion after the MYL2 gene
locus as MYL2Neo/w or MYL2EGFP/w hESCs respectively.
MYL2Neo/w and MYL2EGFP/w hESCs maintained pluripotency
and cardiac differentiation capacities
Under normal culture conditions, MYL2Neo/w and
MYL2EGFP/w hESCs maintained typical clonal morpholo-
gies and expressed strong alkaline phosphatase activities as
normal hESCs did. Immunofluorescence staining showed
that these cells expressed pluripotency markers OCT4,
SOX2, Nanog, and SSEA-4 (Fig. 2a). Quantitative PCR also
showed that the expression level of the pluripotency genes
OCT4, SOX2, Klf4, and c-MYC in MYL2Neo/w and
MYL2EGFP/w hESCs were similar to those in the wildtype
hESCs (H7) (Fig. 2b). Upon injection into immunodefi-
cient mice, MYL2Neo/w and MYL2EGFP/w hESCs formed
teratomas containing the three embryonic germ layers
(Fig. 2c). These results indicated that insertion of the
neomycin or EGFP cassette after the MYL2 locus in hESCs
did not affect their pluripotent potential.
We next differentiated MYL2Neo/w and MYL2EGFP/w
hESCs into the cardiac lineage using a modified 2D
directed cardiac differentiation protocol [6]. The differ-
entiated cells usually started to beat spontaneously on
day 8 or 9 after differentiation (Additional file 5: Video S1).
We consistently obtained greater than 90% of the dif-
ferentiated cells being cTnT-positive cardiomyocytes by
fluorescence-activated cell sorting (FACS) analysis in
our routine differentiation protocol (Fig. 2d). Further,
MLC-2v expression markedly increased along directed
cardiac differentiation and become stable after day 25
post differentiation. In addition, neomycin phospho-
transferase II and GFP proteins were simultaneously
expressed (Additional file 6: Figure S3), indicating again
the correct insertion and expression of the selection
system. Immunofluorescence staining of the differentiated
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Fig. 1 (See legend on next page.)
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beating cells showed that they expressed cardiomyocyte-
specific markers cTnT, sarcomeric α-actinin, MLC-2v, and
MLC-2a (Fig. 2e). These results indicated a successful car-
diac differentiation and the correct selection system for
the MYL2Neo/w and MYL2EGFP/w hESCs.
Effective enrichment of MLC-2v-positive human early
ventricular cardiomyocytes based on neomycin selection
Compared to cells differentiated from wildtype hESCs
(H7) that all died after G418 selection, cardiomyocytes
differentiated from MYL2Neo/w hESCs survived and
maintained normal cellular growth as well as beating ac-
tivities under the stress of G418 selection (Fig. 3a and
Additional file 7: Video S2). FACS analysis of the differ-
entiated MYL2Neo/w hESCs based on anti-human MLC-2v
antibodies indicated that the percentage of MLC-2v-
positive cardiomyocytes increased from ~ 80% before
G418 selection to > 98% after G418 selection (Fig. 3b).
Immunofluorescence staining indicated the percentage of
MLC-2v-positive cells over cTnT-positive cardiomyocytes.
G418 selection significantly enriched MLC-2v/cTnT
double-positive cardiomyocytes derived from MYL2Neo/w
hESCs from~ 78% to ~ 98% (Fig. 3c, d). Quantitative PCR
showed ventricular markers MYL2 and HAND1 were sig-
nificantly upregulated (Fig. 3e), while atrial markers GJA5,
TBX5, and MYH6 (Fig. 3f) and sinus nodal markers
SHOX2, TBX3, and TBX18 (Fig. 3g) were significantly re-
duced after G418 selection. Of note, expression of CX43,
which encodes the predominant cardiac gap-junction
protein, was not significantly different with the control
(Additional file 8: Figure S4b), indicating that G418 selec-
tion did not affect expression of normal junctional pro-
teins of these cardiomyocytes.
Multielectrode array analysis showed that G418-
selected MLC-2v/cTnT double-positive cardiomyocytes
exhibited normal electrophysiology, longer field poten-
tial duration, and lower beating rate, suggesting they
were closer to the ventricular form of cardiomyocytes
(Fig. 3 h and Additional file 8: Figure S4c, d). We next
examined the electrophysiological properties of these
MLC-2v-positive cardiomyocytes by whole cell patch
clamping. Compared to nonselected MYL2Neo/w hESC-
derived cardiomyocytes that contained ~ 55% cells
exhibiting ventricular-like action potentials, G418 selec-
tion markedly increased the percentage of cells with
ventricular-like action potentials and reduced the per-
centage of cells with atrial-like and nodal-like action
potentials (Fig. 3i and Additional file 9: Table S3). Over-
all, these results indicated that the neomycin selection
cassette inserted following the MYL2 gene is effective
in enrichment of MLC-2v-positive early ventricular
cardiomyocytes.
Effective enrichment of MYL2-positive human early
ventricular cardiomyocytes based on EGFP selection
We next tested whether genomic EGFP insertion after
the MYL2 gene can be used to enrich MLC-2v-positive
early ventricular cardiomyocytes by flow cytometry.
FACS showed that there were ~ 10.4% EGFP-positive
cells at day 25 post cardiac differentiation of the
MYL2EGFP/w hESCs (Fig. 4a). We then sorted out these
EGFP-positive cells and maintained them in culture.
These cells exhibited relative weak EGFP expressions
possibly because of the low copy number due to only
one allele insertion of the EGFP cassette in the genome
(Fig. 4b). The EGFP-positive cells all showed strong
MLC-2v and cTnT expression but very dim MLC-2a
expression at the same time (Fig. 4c, d). After FACS se-
lection, MYL2EGFP/w-CMs survived well and maintained
spontaneous contraction (Additional file 10: Video S3).
Assessment of viability showed ~ 83.8% of these cells
remained active (Fig. 4e). Whole cell patch clamping
showed that almost all of the EGFP-positive cells
(~91.3%) exhibited ventricular-like action potentials
(Fig. 4f and Additional file 11: Table S4). These results
showed that, although the expression is weak, EGFP
inserted after the MYL2 locus is effective to enrich
MLC-2v-positive early ventricular cardiomyocytes from
cardiac differentiation of hESCs.
Enrichment of human MLC-2v-positive early ventricular
cardiomyocytes from hiPSCs
In the future, hiPSCs could be a powerful tool and
widely used for personalized regenerative medicine.
To see whether our MYL2Neo/w and MYL2EGFP/w
systems also work in hiPSCs as in hESCs, we next
(See figure on previous page.)
Fig. 1 Schematics of the strategy for inserting the neomycin and EGFP selection cassette into the MYL2 locus. a TALENs targeting site for the
MYL2 gene and the homologous recombination events. Red arrow indicates the stop codon of MYL2 gene. After introduction of a double-strand
break near the MYL2 exon 7 after the stop codon by TALENs, an IRES-Neo (donor 1) or P2A-EGFP (donor 2) along with an excisable PGK-Puromycin
drug selection cassette sequence was inserted into the MYL2 locus downstream of the TAG stop codon (middle panel). The bottom panel shows the
targeted genomic locus after Cre-mediated excision of the Puro selection cassette. Blue box, exon of the MYL2 gene. b Nested-PCR strategy to identify
successfully targeted clones. Both gels indicated 10 out of 14 clones had at least one copy of the targeted allele (targeting efficiency was 71.5%). MYL2
myosin light chain 2, TALEN transcription activator-like (TAL) effector nuclease, IRES internal ribosome entry site, P2A self-cleaving peptide sequence,
Neo neomycin resistant cassette, EGFP enhanced green fluorescent protein, PGK phosphoglycerol kinase promoter, Puro puromycin resistance gene,
polyA polyadenylation sequence, 5’arm 5’-homology arms, 3’arm 3’-homology arms
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transfected hiPSCs generated in our laboratory [19]
using the TALEN pair L2/R2 and the respective
donor construct by electroporation to insert the neo-
mycin/EGFP selection marker under the C-terminus
of the MYL2 gene. These heterozygous hiPSCs with
neomycin or EGFP insertion after the endogenous
MYL2 gene locus were termed MYL2Neo/w-hiPSCs
and MYL2EGFP/w-hiPSCs respectively. As shown in
Fig. 2 MYL2Neo/w and MYL2EGFP/w hESCs maintained pluripotency and the ability to differentiate into highly pure cardiomyocytes. a MYL2Neo/w
and MYL2EGFP/w hESCs maintained pluripotent stem cell morphology (bright field (BF)), positive alkaline phosphatase (AP) staining, and expression
of the pluripotency markers OCT4, SOX2, Nanog, and SSEA-4. Scale bars, 200 μm. b Quantitative PCR examining endogenous expression of the
pluripotency factors relative to GAPDH in MYL2Neo/w and MYL2EGFP/w hESCs. Data obtained from three independent experiments. Wildtype hESCs
(H7) used as controls. c Undifferentiated MYL2Neo/w and MYL2EGFP/w hESCs formed teratomas, which exhibited tissues of all three developmental
germ layers: ectoderm (e.g., sebaceous gland cells), mesoderm (e.g., cartilage cells), and endoderm (e.g., gland cells). Scale bars, 200 μm. d Purity of
MYL2Neo/w and MYL2EGFP/w hESC-derived cardiomyocytes detected by flow cytometry analysis of cardiac specific marker cTnT. e Immunostaining
showing MYL2Neo/w and MYL2EGFP/w hESC-derived cardiomyocytes expressed cardiomyocyte specific proteins sarcomeric α-actinin, cTnT, MLC-2v, and
MLC-2a. Scale bars, 50 μm. EGFP enhanced green fluorescent protein, MLC-2v cardiac ventricular isoform of myosin light chain-2, MYL2 myosin light
chain 2
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Fig. 3 Effective enrichment of MLC-2v-positive human early ventricular cardiomyocytes based on the neomycin selection system. a Compared with
the wildtype control (H7-derived cardiomyocytes), MYL2Neo/w hESC-derived cardiomyocytes show normal growth following G418 selection for 8–10
days after plating, while control cells died completely. b Flow cytometry analysis shows a higher percentage of MLC-2v-positive cells derived from
MYL2Neo/w hESCs post G418 selection. c Representative immunofluorescence staining images reveal that MLC-2v was expressed in almost all of the
G418 selected cTnT-positive MYL2Neo/w hESC-derived cardiomyocytes, while in control cells without G418 selection only partial cells showed MLC-2v
expression. Scale bars, 100 μm. d Quantification of MLC-2v/cTnT expression ratio in MYL2Neo/w hESC-derived cardiomyocytes before and post G418
selection. n = 298, ***P < 0.001 by two-tailed Student’s t test. e–g Quantitative PCR showing expression of ventricular markers MYL2 and HAND1 (e) was
significantly upregulated, while atrial markers GJA5, TBX5, and MYH6 (f) and nodal markers SHOX2, TBX3, and TBX18 (g) were significantly reduced in
MYL2Neo/w hESC-derived cardiomyocytes post G418 selection. Data shown as the mean ± SEM of three independent experiments. *P < 0.05;
**P < 0.01; ns not statistically significant by two-tailed Student’s t test. h Quantification of beating rates for MYL2Neo/w hESC-derived cardiomyocytes
in response to cardiac pharmaceutical reagents before and post G418 selection. i Percentages of ventricular-like, atrial-like, and nodal-like cells
produced from MYL2Neo/w hESC-derived cardiomyocytes 30 days after cardiac differentiation before and post G418 selection as determined by
single cell patch clamp. MYL2 myosin light chain 2, V-like ventricular-like cells, A-like atrial-like cells, N-like nodal-like cells
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Fig. 4 (See legend on next page.)
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Additional file 12: Figure S5 and Additional file 13:
Figure S6, our MYL2Neo/w and MYL2EGFP/w systems also
work in hiPSCs.
Coculture with neonatal rat ventricular myocytes
To investigate the regenerative therapy potential of these
hPSC-derived ventricular cardiomyocytes, we cocultured
neonatal rat ventricular myocytes (NRVMs) with the se-
lected MYL2Neo/w-CMs (NN-co-cultures) or MYL2EGFP/w-
CMs (NE-co-cultures) in a ratio of 3:1 (Additional file 14:
Video S4 and Additional file 15: Video S5). Bright field
micrograph showed that NRVMs, as well as NN-co-
cultures, formed confluent monolayers. Immunofluores-
cence staining analyses confirmed a mixture of NRVMs
(DAPI+ cells) and G418 selected MYL2Neo/w-CMs (HNA
+/DAPI+ cells) in NN-co-cultures (Fig. 5a). Importantly,
the same as NRVMs, these NN-co-cultures expressed
CX43 (Fig. 5a), which play an important role in the forma-
tion of gap junctions between ventricular cardiomyocytes,
indicating that the cocultures formed cardiac junctions.
Next, we performed multielectrode arrays (MEAs) to
investigate the synchronous activities of the NN-co-
cultures and NE-co-cultures. Both showed regular and
synchronous electrical activities similar to NRVM elec-
trophysiological characteristics (Fig. 5b and 5c),
Addition of hPSC-derived ventricular cardiomyocytes
to NRVMs did not increase their arrhythmogenicity
(Fig. 5d), suggesting a well-coupled syncytium of the
hPSC-derived ventricular cardiomyocytes and animal
heart cells.
Further maturation of the MLC-2v-positive ventricular-like
cardiomyocytes
For future regenerative therapy of adult human heart
damage such as MI, maturation of the hPSC-derived car-
diac cells is a necessary step. In addition, the human
ventricular cardiomyocytes selected using our strategy
exhibited strong MLC-2v expression and residual MLC-
2a expression (Additional file 8: Figure S4a). This pat-
tern was actually consistent with the MLC-2a expression
during embryogenesis. Not like MLC-2v is restrictively
expressed in the ventricular segment, MLC-2a is
uniformly expressed throughout the whole heart tube at
E8.0 in mice [21]. With further maturation of the ventri-
cles, MLC-2a expression is downregulated and disap-
pears by E13.5 in ventricular chambers and is only
expressed in the atria. Thus, further maturation of the
selected MLC-2v-positive cardiomyocytes should better
direct them into the ventricular lineage. We thus next
sought to further induce maturation of the enriched
MLC-2v-positive early ventricular cardiomyocytes [22].
Culturing the MLC-2v-positive cardiomyocytes with the
maturation medium greatly enhanced the organization
of the myofilaments (Fig. 6a), the cell size (Fig. 6b),
and the sarcomere length of these cells (Fig. 6c). The
percentage of cells with multiple nuclei, an indicator
of cardiomyocyte maturation, also greatly increased
(Fig. 6d). Expression levels of functional and mature
genes MYL2, MYL7, MYH6, MYH7, TNNT2, CX43,
ACTN2, CACNA1C, MYOM1, and RYR2 were all up-
regulated in the further matured MYL2-positive cardi-
omyocytes (Fig. 6e). The ratios of MYL2/MYL7 and
MYH7/MYH6, which indicate maturation of heart tissues,
were also significantly increased (Fig. 6e). Calcium tran-
sients of the maturation medium-cultured MLC-2v-
positive cardiomyocytes were much larger than those of
the nonmatured cells. The transient amplitude, maximum
upstroke velocity, and maximum decay velocity were all
significantly increased (Fig. 6f). All these results demon-
strate further maturation of the selected MLC-2v-positive
cardiomyocytes.
Preparation of engineered human ventricular heart
muscles using selected MLC-2v-positive ventricular
cardiomyocytes
For the scaffold of the engineered tissues, we used
decellularized natural heart ECM [19, 23, 24] by perfu-
sion of native rat cadaveric heart with detergents
(Fig. 7a). Immunofluorescence staining was used to
detect ECM compositions. Laminin, fibronectin, and
collagen III, which are major proteins of the ECM,
remained present within the decellularized heart matri-
ces after removal of cells (Fig. 7b). Nonmyocytes such
as fibroblasts are also another indispensable component
(See figure on previous page.)
Fig. 4 Effective enrichment of MLC-2v-positive human early ventricular cardiomyocytes based on the EGFP selection system. a FACS sorting showing
positive cardiomyocytes derived from MYL2EGFP/w hESCs 25 days after cardiac differentiation. b Representative green fluorescence (EGFP), bright field
(BFEGFP), and merged images of MYL2EGFP/w hESC-derived cardiomyocytes before and after FACS sorting. Scale bars, 100 μm. c Immunofluorescence
microscopy showing coexpression of EGFP and MLC-2v in FACS sorted MYL2EGFP/w hESC-derived cardiomyocytes. Scale bars, 50 μm. d Double
immunofluorescence staining showing coexpression of EGFP and MLC-2v in FACS sorted MYL2EGFP/w hESC-derived cardiomyocytes (1). MLC-2v was
expressed in all of the cTnT-positive MYL2EGFP/w hESC-derived cardiomyocytes post FACS (2). MLC-2a only showed background expression level in the
cTnT-positive MYL2EGFP/w hESC-derived cardiomyocytes post FACS (3). Scale bars, 100 μm. e Vitality assessment of the FACS selected MYL2EGFP/w-CMs
by live cell staining for markers of apoptosis. Representative graph as detected by flow cytometry analysis. f Percentages of ventricular-like, atrial-like,
and nodal-like cells produced from MYL2EGFP/w-CMs before and after FACS sorting as determined by single cell patch clamp. EGFP enhanced green
fluorescent protein, MLC-2v cardiac ventricular isoform of myosin light chain-2, V-like ventricular-like cells, A-like atrial-like cells, N-like nodal-like cells
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for bioengineered heart tissues [25]. In this study, we used
mesenchymal cells derived from Warton's jelly of the hu-
man umbilical cord as the nonmyocyte component [26].
To yield optimal structural and functional properties for
EHTs [27], we used the combination of hPSC-derived 75%
ventricular cardiomyocytes and 25% umbilical cord-
derived nonmyocytes (Fig. 7c). The mixture of cells on
pieces of decellularized native rat heart ECM formed a
compact tissue-like structure after 2 weeks (Fig. 7d and
Additional file 16: Figure S7). H&E and immunofluores-
cence staining indicated that the mixed cardiac cells
attached and grew well on the native heart matrix
(Fig. 7e, f ). Immunofluorescence staining for the coex-
pression of cTnT and α-SMA or vWF indicated the newly
formed tissues contained cardiomyocytes, smooth muscle
cells, and endothelial cells, which are the primary cell
types in human adult heart tissues (Fig. 7g). However,
expression of CD31 was not detectable (data not shown),
suggesting that mature vessels were not fully formed at
this moment. Meanwhile, cardiac gap-junction protein
connexin 43 (CX43) was present at numerous points of
contact between adjacent cells, which promote cell–cell
contact and rapid electrical transmission for the heart
tissues (Fig. 7g).
These engineered ventricular heart muscles exhibited
spontaneous contractile and electrophysiological activ-
ities (Additional file 17: Video S6) and responded well to
pharmaceutical reagents verapamil (Fig. 8a), nifedipine
(Fig. 8b), E4031 (Fig. 8c), and epinepherine/metoprolol
(Fig. 8d) in vitro.
Fig. 5 Coculture experiment showing that hPSC-derived ventricular cardiomyocytes electrically coupled with surrounding NRVMs. a Representative
bright field phase contrast microscopic images (BF) and immunofluorescence staining of NRVM cultures (left panels) and NN-co-cultures, containing
NRVMs and G418 selected MYL2Neo/w-CMs (right panels) in a 3:1 ratio. Cells were stained for cardiac troponin T (cTnT), human nuclear antigen (HNA),
gap-junction protein connexin 43 (CX43), and DAPI. G418 selected MYL2Neo/w-CM nuclei were distinguished from rat nuclei by their positive staining
for HNA. Scale bars, 50 μm. b Typical rhythmic spontaneous field potential recordings in NRVM cultures, NN-co-cultures, and NE-co-cultures (NRVMs
and EGFP-positive MYL2EGFP/w-CMs). Quantification of (c) the beating frequency and (d) the percentage of irregular beats. NRVM neonatal rat ventricular
myocyte, NN-co-culture MYL2Neo/w cardiomyocyte, NE-co-culture MYL2EGFP/w cardiomyocyte, ns not significant
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Discussion
Obtaining a pure population of human ventricular cardi-
omyocytes would greatly strengthen human heart tissue
engineering and regenerative therapy for ventricular
damage. Using TALEN-mediated genomic engineering,
we have successfully inserted the neomycin and EGFP
selection markers directly after the ventricular-specific
MYL2 gene within the genome of hPSCs. In this way,
Fig. 6 Maturation medium leads to further maturation of the MLC-2v-positive ventricular-like cardiomyocytes. a Basal medium (control) and
maturation medium (MM)-treated MYL2Neo/w-hiPSC-derived cardiomyocytes stained with α-actinin (green) and DAPI (blue). Scale bars, 50 μm.
Right panels show enlarged views of the boxed areas in the left merged images, which show detailed α-actinin (green) staining patterns.
Compared to MYL2Neo/w-hiPSC-derived cardiomyocytes cultured in basal medium (control), MM-treated MYL2Neo/w-hiPSC-derived cardiomyocytes
show significant changes in cell size (b), sarcomere length (c), and number of multinuclear cells (d). n > 100 per condition. e Quantitative PCR
showing higher transcriptional expression of the functional and mature genes in MM-treated MYL2Neo/w-CMs compared with control. Gene
expressions shown normalized to GAPDH. Data shown as the mean ± SEM of three independent experiments. *P < 0.05; **P < 0.01; ***P <0.001
by two-tailed Student’s t test. f MYL2Neo/w-CMs show larger calcium transient amplitudes, faster upstroke, and faster decay velocities after culture
with MM. n > 45 per condition
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neomycin or EGFP was coexpressed with MLC-2v in a
separate form when hPSCs were differentiated into car-
diomyocytes. Based on these markers, we were able to
enrich highly pure human early ventricular cardiomyo-
cytes from hPSC cardiac differentiation and use them
for construction of engineered human ventricular heart
muscles.
Previous studies used a different strategy than ours
to select hiPSC-derived early ventricular myocytes.
They produced either lentiviruses or adenoviruses car-
rying MYL2 promoter-driving fluorescent proteins,
generated stable infected hPSC lines or infected
hiPSC-derived cardiomyocytes, and then collected the
MLC-2v-positive cardiomyocytes by FACS [17, 18, 28].
However, there are certain limitations of virus-based
techniques: the virus infection rate is usually low in
hiPSC-derived human cardiomyocytes and this will
lead to a waste of many noninfected cardiomyocytes
[17]; and using viruses raises safety issues and causes
the problem of ectopic genomic insertion and leak
expression, which further compromises the purity of
selected ventricular cells and their future clinical use.
(See figure on previous page.)
Fig. 7 Generation and histological analysis of the human ventricular heart muscles. a Process of decellularization of rat hearts and preparation of
natural heart ECM. b Major ECM compositions (laminin, fibronectin, and collagen III) of decellularized hearts and native rat hearts detected by
immunofluorescence staining. c Schematic diagram of the preparation of engineered human heart muscles using MLC-2v-positive ventricular
cardiomyocytes. d Representative image of the engineered human ventricular heart muscles in a light microscope. Scale bar, 200 μm. H&E
staining (e) and coimmunostaining by anti-MLC-2v and anti-collagen III antibodies (f) of sections of constructed ventricular heart muscles. hPSC-derived
ventricular cardiomyocytes are well distributed and attached on the native ECM. Scale bar, 100 μm. g Double immunofluorescence staining
for cTnT/α-smooth muscle actin (α-SMA), cTnT/von Willebrand factor (vWF), and cTnT/CX43 in the engineered human ventricular heart muscles. Scale
bars, 100 μm. ECM extracellular matrix, MLC-2v cardiac ventricular isoform of myosin light chain-2, hMSCs human mesenchymal stem cells
Fig. 8 Electrophysiology analysis of human ventricular heart muscles. a–d Ventricular heart muscles exhibited normal electrophysiology and
responded to cardiac pharmaceutical reagents. MEA recording of the field potentials and contraction rate of the engineered human heart
muscles before (baseline) and after treatment of verapamil (a), nifedipine (b), E4031 (c), and epinephrine and metoprolol (d). Data shown as the
mean ± SEM of three independent experiments. *P < 0.05 compared with baseline; *##P < 0.05 compared with epinephrine alone by two-tailed
Student’s t test
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Our method avoided the disadvantages of virus-based
strategies and will be more suitable for future clinical
applications.
In terms of selection efficiency, our neomycin-based
drug selection strategy yielded a very high efficiency
and purity (~99%) of MLC-2v-positive hPSC-derived
cardiomyocytes. The EGFP-based selection strategy
yielded a ~ 10.4% efficiency in sorting pure MLC-2v-
positive cardiomyocytes from cardiac differentiation of
hPSCs by FACS. This could be due to the relative weak
EGFP expressions because of only one allele insertion
of the EGFP cassette after the MYL2 locus. Homozy-
gous insertion of the EGFP cassette may further
increase the EGFP expression level as well as the result-
ing selection efficiency and should be examined in the
future. Of note, a recent pioneer study developed strat-
egies for selection of mouse ESC-derived ventricular-like
cardiomyocytes based on molecular beacons (MBs) target-
ing the ventricular specific gene IRX4 [29]. However, the
transfection efficiency of the MBs targeting IRX4 in hu-
man PSC-derived cardiomyocytes was not reported and
remains to be investigated. Our neomycin-based selec-
tion strategy exhibited ~ 99% efficiency in enrichment
of human MLC-2v-positive ventricular cardiomyocytes
and avoided steps of FACS in the MB method, which
further reduced the chance of contamination by flow
cytometry.
By combining decellularized native heart matrix as
the scaffold, the selected pure hPSC-derived early ven-
tricular cardiomyocytes, and mesenchymal cells derived
from Warton's jelly of human umbilical cord as the
nonmyocyte component, we further constructed pieces
of engineered human ventricular heart muscles with
different sizes and shapes. These engineered human
ventricular heart muscle constructs responded well to
pharmaceutical agents specific to heart physiologies in-
cluding epinephrine, nifedipine, E4031, and verapamil.
Of note, although we used 75% ventricular myocytes
and 25% nonmyocytes [27] to make these constructs,
the optimal percentage of myocytes and nonmyocytes
should be determined in the future. The treatment
effect of these human ventricular heart muscles for
ventricular myocardial damages should be further
tested. In the future, it is feasible to use our method to
construct functional individual-specific ventricular car-
diac patches based on hPSCs for ventricular disease
modeling, drug screening, as well as personalized re-
generative therapy for ventricular damage.
Conclusions
This study provides a novel and effective system for
isolating hPSC-derived ventricular cardiomyocytes by
introducing genetic constructs into hPSCs using TALEN-
mediated genomic editing. Clinical-scale homogeneous
human ventricular-specific cardiomyocytes could be iso-
lated based on G418 selection or flow cytometry. When
combined with promoting maturation and using decellu-
larized natural heart ECM as the scaffold, our study for
the first time constructed functional engineered human
ventricular muscles of desired shape and size in a dish.
Overall we believe these engineered human ventricular
heart muscles should have great potential in cardiac trans-
plantation studies and cardiovascular research.
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Additional file 2: Figure S1. Showing TALEN pairs designed for
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locus of MYL2 and DNA sequencing. Sequencing results of the MYL2
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for the MYL2 targeting locus. Ten potential TALEN off-target sites were
estimated by the TALENoffer software. All 10 sites were amplified by PCR
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Additional file 5: Video S1. showing spontaneous beating of
hPSC-derived cardiomyocytes observed 8–9 days after directed
cardiac differentiation of hPSCs. (MP4 7630 kb)
Additional file 6: Figure S3. Showing the targeted clones presented
changed MLC-2v expression and effective neomycin or EGFP expression.
a Real-time PCR examining MLC-2v expression change post cardiomyocyte
differentiation. Data were mean of three experimental replicates. b Western
blot analysis of the MYL2Neo/w hESC-derived cardiomyocytes expressing
neomycin phosphotransferase II (Neo) (upper panel) and MYL2EGFP/w hESC-
derived cardiomyocytes expressing EGFP protein (lower panel). (JPG 82 kb)
Additional file 7: Video S2. Showing cardiomyocytes differentiated
from MYL2Neo/w hESCs maintained cellular growth and beating activities
under the stress of G418 selection. (MP4 18000 kb)
Additional file 8: Figure S4. Showing the MYL2Neo/w system was
effective in selection of MLC-2v-positive cardiomyocytes. a Compared
with controls, immunostaining for MLC-2a showed a background level
after G418 selection. Nuclei were stained with DAPI (blue). Scale bars,
100 μm. b Expression of CX43 was comparable before and after G418
selection. c Representative traces of MEA showing field potentials (heart
beats) recorded in MYL2Neo/w hESC-derived cardiomyocytes before and
post G418 selection, followed by application of a β-adrenergic agonist
(Epineprine (Epn), 10 μM) and antagonist (Metoprolol (Mtl), 100 μM).
d Quantification of the beating rate of MYL2Neo/w-hPSC-derived ventricular
cardiomyocytes (vCMs) and hPSC-derived wildtype cardiomyocytes (CMs)
cultured in DMEM with 10% FBS. (JPG 238 kb)
Additional file 9: Table S3. Presenting whole-cell patch clamp
recordings of action potentials of ventricular-like, atrial-like, and nodal-like
cells produced from day 30 MYL2Neo/w-derived cardiomyocytes before and
post G418 selection. (DOCX 17 kb)
Additional file 10: Video S3. Showing FACS selected MYL2EGFP/w-CMs
maintained cellular growth and spontaneous beating. (MP4 2520 kb)
Li et al. Stem Cell Research & Therapy  (2017) 8:202 Page 16 of 18
Additional file 11: Table S4. Presenting whole-cell patch clamp
recordings of action potentials of ventricular-like, atrial-like, and nodal-like
cells produced from day 30 MYL2EGFP/w-derived cardiomyocytes before
and post FACS sorting. (DOCX 16 kb)
Additional file 12: Figure S5. Showing analyses of pluripotency in
representative hiPSC clones. a, b MYL2Neo/w-hiPSCs and MYL2EGFP/w-
hiPSCs exhibited similar morphologies, alkaline phosphatase activities,
and expression levels for the pluripotent genes OCT4, SOX2, Klf4, and
c-MYC to those in wildtype hiPSCs. Scale bars, 200 μm. (JPG 266 kb)
Additional file 13: Figure S6. Showing enrichment of human MLC-
2v-positive early ventricular cardiomyocytes from hiPSCs. a, b Adding
G418 after cardiac differentiation of MYL2Neo/w-hiPSCs successfully
selected cardiomyocytes and markedly increased the percentage of
MLC-2v-positive cells to ~ 98%. c Immunostaining also showed that,
after G418 selection, MLC-2v-positive cardiomyocytes were enriched while
MLC-2a-positive cardiomyocytes were almost completely removed. d FACS
sorting based on GFP expression after cardiac differentiation of MYL2EGFP/w-
hiPSCs successfully enriched pure MLC-2v-positive early ventricular
cardiomyocytes. Almost 100% of these EGFP+ cells showed strong MLC-2v
expression in cTnT-positive cardiomyocytes. (JPG 475 kb)
Additional file 14: Video S4. Showing a typical video of NN-co-cultures
under phase-contrast microscopy. (MP4 2200 kb)
Additional file 15: Video S5. Showing a typical video overlapping
bright field and EGFP images of NE-co-cultures. (MP4 1580 kb)
Additional file 16: Figure S7. Showing the different sizes and shapes
of the engineered ventricular muscles. (JPG 31 kb)
Additional file 17: Video S6. Showing a representative video showing
an engineered human ventricular heart muscles cultured on
multielectrode arrays. (MP4 3040 kb)
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